ProActive Capital Resources Group has received compensation from Organovo, to provide research and investor relations coverage for a period of time.
Organovo (NASDAQ:ONVO) is an emerging life science company that is developing innovative three-dimensional (3D) biology capabilities to create tissue on demand for research (e.g. drug discovery and toxicology) and surgical applications (e.g. therapeutic regenerative medicine implants) based on its proprietary NovoGen MMX Bioprinter technology (YouTube video: http://youtu.be/80DhBLEhdzk).
The tremendous game-changing potential for this technology was recently featured in a Wall Street Journal article (available at http://online.wsj.com/article/SB10000872396390443816804578002101200151098.html).
The Company is advancing beyond the current 2D mono-layer cell standard in the life science industry by creating 3D human tissue constructs comprised entirely of cells to better replicate human biology inside the body (in vivo) with the advantage of lab-based (in vitro) applications that do not depend on human or animal subjects for testing purposes.
$ONVO has broad intellectual property (NYSE:IP) rights including exclusive licenses from the University of Missouri-Columbia and Clemson University in addition to full ownership of six pending patent applications related to 3D bio-printing technology.
The Company's three-part business model includes the following:
1.) Preclinical drug discovery activities (development milestone and royalty-based business model) such as research agreements with pharmaceutical and biotech companies including current agreements with Pfizer (NYSE:PFE) to develop 3D tissue models for drug development purposes and United Therapeutics (NASDAQ:UTHR) to discover new treatments for a lung condition (pulmonary hypertension).
2.) Life science research tools (product sales-based business model) such as pharmacokinetic (ADME or absorption, distribution, metabolism and excretion)testing for experimental drug compounds and toxicology (TOX) testing (e.g. liver TOX testing is very common since this is the primary route of metabolism for most drugs) to predict how drugs will in humans without subjecting people or animals to testing with experimental compounds.
3.) A next-generation strategy for regenerative medicine that offers the potential for 3D tissue constructs comprised entirely of functional cells without the need for non-cellular scaffold or bio-material components for surgical implantation to restore normal organ or tissue function in humans following acute or chronic damage or injury with the potential to erase the need for organ transplants / rejection since this technology utilizes a patient's own cells.
$ONVO anticipates new agreements with biotech and/or pharmaceutical companies within the next 18-24 months and has increased its resources on both business development and R&D (research and development) to improve the conversion rate (i.e. from negotiations to signed deals) and the terms of drug discovery pacts such as the current agreements with $PFE and $UTHR (i.e. from low to mid/high single-digit royalties and $10M to $20M+ development milestone payments), which are expected to generate revenue during 2H12.
The Company's goal is to both talk with more companies regarding potential agreements (business development) while simultaneously generating data (R&D) that is published in peer-reviewed scientific journals to validate the 3D bio-printing technology (e.g. liver TOX data). $ONVO also plans to enter strategic technology partnerships with bio-engineering focused companies that may specialize in complementary areas such as cell growth mediums.
While the process of preclinical drug discovery and development is a lengthy, risky one; $ONVO represents a truly innovative life science company with the potential to change how drugs are discovered, developed and tested in addition to tremendous opportunity in the area of tissue/organ repair and/or replacement-possibly erasing the need for organ transplants and the concern of rejection with an initial goal of "printing" new blood vessels that could be used after a heart attack to restore blood flow and minimize damage.